Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM

Published:September 15, 2022DOI:



      The ileal bile acid transporter inhibitor elobixibat was recently approved in Japan for use in the treatment of patients with chronic constipation. Elobixibat has been associated with increased plasma glucagon-like peptide 1 level through Takeda G protein receptor 5, which is a membrane receptor of bile acids. The present study assessed the metabolic effects of elobixibat in patients with type 2 diabetes mellitus (T2DM)-related constipation.


      In this single-arm pilot study, 21 patients with T2DM and constipation were administered elobixibat 10 mg/d for 12 weeks (period 1). The primary end point was the change in hemoglobin (Hb) A1c at week 12. Secondary end points included physical parameters; constipation symptoms; and blood parameters, such as low-density lipoprotein cholesterol (LDL-C), arachidonic acid (AA), and fatty acid fractions. Thereafter, the study participants chose whether to continue therapy for an additional 12 weeks (period 2), at which point HbA1c and lipid levels were reevaluated. Safety information, including adverse events, discontinuation and interruption of the drug, was collected at each visit during the trial.


      Period 1: the levels of HbA1c, LDL-C, and AA were significantly reduced after administration of elobixibat for 12 weeks (–0.2%, –21.4 mg/dL, and –16.1 µg/dL, respectively; P = 0.016, P < 0.001, and P = 0.010). Period 2: at week 24, the change from baseline in HbA1c was significantly greater among those who continued elobixibat treatment than in those who discontinued after 12 weeks (–0.23% vs +0.21%; P = 0.038). No serious or severe adverse events were observed.


      Elobixibat may benefit patients with T2DM by improving glucose metabolism and lowering serum LDL-C and AA levels, in addition to ameliorating constipation. This single-arm pilot study was of a small sample size. The findings provide a basis for designing a larger-scale study to confirm the effects of elobixibat on glucose and lipid metabolism. (UMIN Clinical Trials Registry identifier: UMIN000045508;


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chiang JY.
        Bile acid metabolism and signaling.
        Compr Physiol. 2013; 3: 1191-1212
        • Lu TT
        • Repa JJ
        • Mangelsdorf DJ.
        Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism.
        J Biol Chem. 2001; 276: 37735-37738
        • Stofan M
        • Guo GL.
        Bile acids and FXR: novel targets for liver diseases.
        Front Med (Lausanne). 2020; 7: 544
        • Watanabe M
        • Houten SM
        • Wang L
        • Moschetta A
        • Mangelsdorf DJ
        • Heyman RA
        • et al.
        Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.
        J Clin Invest. 2004; 113: 1408-1418
        • Ticho AL
        • Malhotra P
        • Dudeja PK
        • Gill RK
        • WA Alrefai
        Intestinal absorption of bile acids in health and disease.
        Compr Physiol. 2011; 10: 21-56
        • Broeders EP
        • Nascimento EB
        • Havekes B
        • Brans B
        • Roumans KH
        • Tailleux A
        • et al.
        The bile acid chenodeoxycholic acid increases human Brown adipose tissue activity.
        Cell Metab. 2015; 22: 418-426
        • Pathak P
        • Xie C
        • Nichols RG
        • Ferrell JM
        • Boehme S
        • Krausz KW
        • et al.
        Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signalising to improve metabolism.
        Hepatology. 2018; 68: 1574-1588
        • Maruyama T
        • Miyamoto Y
        • Nakamura T
        • Tamai Y
        • Okada H
        • Sugiyama E
        • Itadani H
        • Tanaka K.
        Identification of membrane-type receptor for bile acids (M-BAR).
        Biochem Biophys Res Commun. 2002; 298: 714-719
        • Harach T
        • Pols TW
        • Nomura M
        • Maida A
        • Watanabe M
        • Auwerx J
        • et al.
        TGR5 potentiates GLP-1 secretion in response to anionic exchange resins.
        Sci Rep. 2012; 30: 1-7
        • Katsuma S
        • Hirasawa A
        • Tsujimoto G.
        Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1.
        Biochem Biophys Res Commun. 2005; 329: 386-390
        • Nakajima A
        • Seki M
        • Taniguchi S
        • Ohta A
        • Gillberg PG
        • Mattsson JP
        • Camilleri M.
        Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
        Lancet Gastroenterol Hepatol. 2018; 3: 537-547
        • Acosta A
        • Camilleri M.
        Elobixibat and its potential role in chronic idiopathic constipation.
        Ther Adv Gastroenterol. 2014; 7: 167-175
        • Simrén M
        • Bajor A
        • Gillberg PG
        • Rudling M
        • Abrahamsson H.
        Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation—a double-blind study.
        Aliment Pharmacol Ther. 2011; 34: 41-50
        • Chedid V
        • Vijayvargiya P
        • Camilleri M.
        Elobixibat for the treatment of constipation.
        Expert Rev Gastroenterol Hepatol. 2018; 12: 951-960
        • Rudling M
        • Camilleri M
        • Graffner H
        • Holst JJ
        • Rikner L.
        Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
        BMC Cardiovasc Disord. 2015; 15: 1-8
        • Concepción-Zavaleta MJ
        • Gonzáles Yovera JG
        • Moreno Marreros DM
        • Rafael Robles LDP
        • Palomino Taype KR
        • Soto Gálvez KN
        • et al.
        Diabetic gastroenteropathy: an underdiagnosed complication.
        World J Diabetes. 2021; 12 (PMID3416872): 794-809
        • Brufau G
        • Stellaard F
        • Prado K
        • Bloks VW
        • Jonkers E
        • Boverhof R
        • Kuipers F
        • Murphy EJ.
        Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism.
        Hepatology. 2010; 52: 1455-1464
        • Drossman DA
        • Hasler WL.
        Rome IV-functional GI disorders: disorders of gut-brain interaction.
        Gastroenterology. 2016; : 1501257-1501261
        • Watanabe M
        • Houten SM
        • Mataki C
        • Christoffolete MA
        • Kim BW
        • Sato H
        • et al.
        Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
        Nature. 2006; 439: 484-489
        • Yamakawa T
        • Takano T.
        Result of the Glucose-Lowering Effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.
        Clin Ther. 2007; 29: 74-83
        • Pols TW
        • Nomura M
        • Harach T
        • Lo Sasso G
        • Oosterveer MH
        • Thomas C
        • et al.
        TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading.
        Cell Metab. 2011; 14: 747-757
        • Haselow K
        • Bode JG
        • Wammers M
        • Ehlting C
        • Keitel V
        • Kleinebrecht L
        • et al.
        Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages.
        J Leukoc Biol. 2013; 94: 1253-1264
        • Ma K
        • Saha PK
        • Chan L
        • Moore DD.
        Farnesoid X receptor is essential for normal glucose homeostasis.
        J Clin Invest. 2006; 116: 1102-1109
        • Kliewer SA
        • Mangelsdorf DJ.
        Bile acids as hormones: the FXR-FGF15/19 pathway.
        Dig Dis. 2015; 33: 327-331
        • Prawitt J
        • Abdelkarim M
        • Stroeve JH
        • Popescu I
        • Duez H
        • Velagapudi VR
        • et al.
        Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity.
        Diabetes. 2011; 60: 1861-1871
        • Wang XH
        • Xu F
        • Cheng M
        • Wang X
        • Zhang DM
        • Zhao LH
        • et al.
        Fasting serum total bile acid levels are associated with insulin sensitivity, islet β-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes.
        Endocr J. 2020; 67: 1107-1117
        • Kuno T
        • Hirayama-Kurogi M
        • Ito S
        • Ohtsuki S.
        Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels.
        Sci Rep. 2018; 8: 1253
        • Watanabe M
        • Morimoto K
        • Houten SM
        • Kaneko-Iwasaki N
        • Sugizaki T
        • Horai Y
        • et al.
        Bile acid binding resin improves metabolic control through the induction of energy expenditure.
        PLoS One. 2012; 7: e38286
        • Tallima H
        • El Ridi R.
        Arachidonic acid: physiological roles and potential health benefits—a review.
        J Adv Res. 2018; 11: 33-41
        • Bäck M.
        Leukotriene signaling in atherosclerosis and ischemia.
        Cardiovasc Drugs Ther. 2009; 23: 41-48
        • Ferretti A
        • Nelson GJ
        • Schmidt PC
        • Kelley DS
        • Bartolini G
        • Flanagan VP.
        Increased dietary arachidonic acid enhances the synthesis of vasoactive eicosanoids in humans.
        Lipids. 1997; 32: 435-439